Press release
Investigation announced for Investors who lost money with shares of HilleVax, Inc. (NASDAQ: HLVX)
An investigation for investors in HilleVax, Inc. (NASDAQ: HLVX) shares over potential securities laws violations by HilleVax, Inc.
Investors who purchased shares of HilleVax, Inc. (NASDAQ: HLVX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of HilleVax, Inc. (NASDAQ: HLVX) concerning whether a series of statements by HilleVax, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Boston, MA based HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
On July 8, 2024, HilleVax, Inc. was the subject of a Fierce Biotech article. According to the article, "HilleVax's stock took a nosedive after the vaccine biotech's sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis (AGE)." The article continues, "The virus-like particle-based vaccine, dubbed HIL-214, missed all primary and secondary endpoints of the NEST-IN1 study of more than 2,800 infants aged about five months of age in the U.S. and Latin America."
Shares of HilleVax, Inc. (NASDAQ: HLVX) declined from $20.22 per share on March 04, 2024, to $1.55 per share on July 08, 2024.
Those who purchased shares of HilleVax, Inc. (NASDAQ: HLVX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of HilleVax, Inc. (NASDAQ: HLVX) here
News-ID: 3644421 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Baxter International I …
An investor, who purchased shares of Baxter International Inc. (NYSE: BAX), filed a lawsuit over alleged violations of Federal Securities Laws by Baxter International Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Baxter International Inc. (NYSE: BAX) have certain options and for certain investors are short and strict deadlines running. Deadline: September 11, 2023. NYSE: BAX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Long-Term Investors in shares of Charter Communicati …
An investigation was announced for current long-term investors in shares of Charter Communications, Inc. (NASDAQ: CHTR) concerning potential breaches of fiduciary duties by certain directors of Charter Communications, Inc.
Investors who are current long term investors in Charter Communications, Inc. (NASDAQ: CHTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
V.F. Corporation (NYSE: VFC) Investor Notice: Deadline in Lawsuit on November 12 …
A deadline is coming up on November 12, 2025 in the lawsuit filed for certain investors of V.F. Corporation (NYSE: VFC) over alleged securities laws violations by V.F. Corporation.
Investors who purchased shares of V.F. Corporation (NYSE: VFC) have certain options and there are strict and short deadlines running. Deadline: November 12, 2025. V.F. Corporation (NYSE: VFC) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According…
Fluor Corporation (NYSE: FLR) Investor Alert: Deadline in Lawsuit on November 14 …
A deadline is coming up on November 14, 2025 in the lawsuit filed for certain investors of Fluor Corporation (NYSE: FLR) over alleged securities laws violations by Fluor Corporation.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and there are strict and short deadlines running. Deadline: November 14, 2025. NYSE: FLR) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
More Releases for HilleVax
Norovirus Infection Pipeline Insight 2025: Advancing Antivirals and Vaccines to …
DelveInsight's "Norovirus Infection - Pipeline Insight, 2025" provides a comprehensive overview of the emerging therapies targeting norovirus, a highly contagious pathogen responsible for acute gastroenteritis outbreaks worldwide. With no approved antivirals or vaccines currently available, management remains limited to supportive care, highlighting a significant unmet medical need.
The pipeline includes promising vaccine candidates, such as virus-like particle (VLP)-based platforms, recombinant protein vaccines, and mRNA technologies designed to induce durable immune protection…
Norovirus Infection Pipeline: 8+ Leading Companies Advancing Breakthrough Vaccin …
The Norovirus infection pipeline is gaining momentum with 8+ pharmaceutical companies pursuing innovative solutions, including Prosit Sole Biotechnology, HilleVax, iosBio, and OstriGen. These players are developing next-generation oral and injectable vaccines, along with antiviral agents targeting viral replication and immune modulation. As Norovirus remains a leading cause of acute gastroenteritis worldwide, the pipeline aims to address critical gaps in prophylaxis and treatment, especially for vulnerable populations like young children and…
Herpes Zoster Pipeline Therapeutics Assessment 2024 (Updated)
DelveInsight's, "Herpes Zoster Pipeline Insight 2024," report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Herpes Zoster Research. Learn more…
Norovirus Vaccine Market to Signify Strong Growth by 2024-2030 | Hillevax, Vaxar …
A new Report by Infinity Business Insights, titled "Norovirus Vaccine Market": Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2030, offers a comprehensive analysis of the industry, which comprises insights on the Norovirus Vaccine market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
Market Overview of Norovirus Vaccine Market: The Norovirus Vaccine market is witnessing significant growth due to the rising prevalence of norovirus…
Growing Demand for Norovirus Vaccine Market is projected to register an impressi …
The "Norovirus Vaccine Market" research report represents major insights on the current growth dynamics as well as the primary revenue generation elements that are available in the Norovirus Vaccine industry along with various other factors over the predicted period 2024-2030. The report on the Norovirus Vaccine market is focusing on a series of parameters including top manufacturing strategies, industry share, prime opportunities, industrial channels, profit margin, etc. The research study…
Major Movements in the Norovirus Vaccine Market Lead to Enhanced Outbreak Prepar …
The Norovirus Vaccine market is experiencing remarkable growth as it plays a crucial role in public health by combatting norovirus infections, a common cause of gastroenteritis worldwide. This press release explores the latest developments and key trends within this dynamic market, which is essential for the prevention of norovirus outbreaks.
The Norovirus Vaccine Market Analysis 2023 Report provides thorough statistical data on the present and historical situation, manufacturing costs, market volume,…
